Tocqueville Asset Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Tocqueville Asset Management’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.04M	Buy	31,250 +7,400	+31%	+$184K	0.01%	370
2026 Q1	$500K	Buy	+23,850	New	+$537K	0.01%	435
2017 Q3	–	Sell	-3,375	Closed	-$210K	–	834
2017 Q2	$210K	Buy	3,375 +250	+8%	+$15.1K	﹤0.01%	742
2017 Q1	$212K	Sell	3,125 -300	-9%	-$22.9K	﹤0.01%	748
2016 Q4	$241K	Sell	3,425 -9,775	-74%	-$693K	﹤0.01%	722
2016 Q3	$936K	Sell	13,200 -3,500	-21%	-$223K	0.01%	515
2016 Q2	$817K	Buy	16,700 +500	+3%	+$32.3K	0.01%	533
2016 Q1	$1.03M	Sell	16,200 -150	-0.9%	-$9.81K	0.01%	499
2015 Q4	$1.83M	Buy	16,350 +5,350	+49%	+$535K	0.02%	438
2015 Q3	$1.06M	Buy	+11,000	New	+$1.26M	0.01%	554

Other funds holding RARE

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $26.9B AUM 34.44% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

FCM

Frontier Capital Management Boston, Massachusetts $10.7B AUM 67.78% 1-Year Est. Return

Tocqueville Asset Management's RARE Position: Q2 2026 in Review

Tocqueville Asset Management increased its Ultragenyx Pharmaceutical (RARE) stake by 31% in Q2 2026, buying an estimated $184K and bringing the position to 31,250 shares worth $1.04M. The position accounts for 0.01% of the portfolio, ranked #370.

Tocqueville Asset Management first reported a position in RARE in Q3 2015 and has held it in 10 quarters since. The position peaked at $1.83M in Q4 2015. 310 funds tracked by Wall St. Rank hold RARE as of Q2 2026.

Tocqueville Asset Management held 31,250 shares of Ultragenyx Pharmaceutical worth $1.04M as of Q2 2026.
Tocqueville Asset Management bought 7,400 Ultragenyx Pharmaceutical shares in Q2 2026, an estimated $184K.
Ultragenyx Pharmaceutical made up 0.01% of Tocqueville Asset Management's portfolio in Q2 2026, its #370 holding.
Tocqueville Asset Management first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and has held it in 10 quarters since.
Tocqueville Asset Management's Ultragenyx Pharmaceutical position peaked at $1.83M in Q4 2015.
310 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2026.

Based on Tocqueville Asset Management's 13F filing for Q2 2026, filed 10 Aug 2026.